Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAYA-PTCy25: Post-transplant cyclophosphamide vs standard GVHD prophylaxis in pediatric/AYA allo-HSCT
jRCTs041260104Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of cyclophosphamide in Acute Leukaemia, lymphosarcoma and myelodysplastic syndrome (MDS) (3 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: GVHD-free, relapse-free survival. Started Aug 2026; status: recruiting.
02
Drugs
cyclophosphamide
03
Conditions
Acute Leukaemialymphosarcomamyelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCTs041260104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041260104.